Dental Program

Peri-Implantitis (PI)

Peri-Implant inflammations represent serious diseases after dental implant treatment, which affect both the surrounding hard and soft tissue. While the lesion of peri-implant mucositis resides in the soft tissues, peri-Implantitis also affects the supporting bone. Peri-Implant mucositis occurs in about 80% of subjects (50% of sites) and peri-Implantitis in between 28% and 56% of subjects (12–40% of sites). Peri-Implantitis can lead to the loss of the implant without multilateral prevention and therapy concepts.

PI treatment

It is assumed that peri-Implant mucositis and peri-Implantitis are caused by bacteria and treatment must include anti-infective measures. Several risk indicators were identified for Peri-Implantitis including (a) poor oral hygiene, (b) a history of Periodontitis, (c) diabetes, (d) smoking, and (e) implant / clinician related factors.

Current standard of care includes mechanical debridement & decontamination, with/without bone grafting, with/without systemic antibiotic.

Our approach

Bone Ssi. Bio’s BS-101 (PeptOss) holistic approach to Peri-Implantitis combines the effect of three in a one easy to use product:

  • Peptide bio-stimulating scaffold

  • Local, sustained delivery of Minocycline HCl (antibiotic)

  • Calcium Phosphate osteoconductive scaffold

 

Orthopedic Program

Osteoarthritis

Osteoarthritis definition:  a disorder involving movable joints characterized by cell stress and extracellular matrix degradation initiated by micro- and macro-injury that activates maladaptive repair responses including pro-inflammatory pathways of innate immunity. The disease manifests first as a molecular derangement (abnormal joint tissue metabolism) followed by anatomic, and/or physiologic derangements (characterized by cartilage degradation, bone remodeling, osteophyte formation, joint inflammation and loss of normal joint function), that can culminate in illness.

Source: Osteoarthritis research society international

Osteoarthritis treatment

Osteoarthritis clinical prevalence is as high as 21.6 percent of the population in the United States, which constitutes direct health costs of over 80 billion US dollars annually. Current therapies, including pain management, improved nutrition and regular programs for exercise, do not lead to the resolution of OA.  Further treatment involves intra-articular injections of corticosteroids, hyaluronic acid or biologics. However, more than half of all individuals with diagnosed symptomatic knee OA have had enough progression of the disease that the only option for them becomes joint replacement.

Joint replacement

More than 3 million total joint replacement surgeries are conducted annually around the globe. From 1999 to 2008, the utilization rate of total knee replacement procedures in the U.S. more than doubled for the overall population and tripled for individuals age 45 to 64.

Coupled with increasing knee OA prevalence, the rising costs of health care may inflict a tremendous economic burden on society in the future. There are currently no medical or surgical treatments that will improve this alarming trajectory. At least 10% joint replacement procedures are revisions.  Infection is the most devastating complication after joint replacements.

Osteoarthritis

Osteoarthritis definition:  a disorder involving movable joints characterized by cell stress and extracellular matrix degradation initiated by micro- and macro-injury that activates maladaptive repair responses including pro-inflammatory pathways of innate immunity. The disease manifests first as a molecular derangement (abnormal joint tissue metabolism) followed by anatomic, and/or physiologic derangements (characterized by cartilage degradation, bone remodeling, osteophyte formation, joint inflammation and loss of normal joint function), that can culminate in illness.

Source: Osteoarthritis research society international

Osteoarthritis treatment

Osteoarthritis clinical prevalence is as high as 21.6 percent of the population in the United States, which constitutes direct health costs of over 80 billion US dollars annually. Current therapies, including pain management, improved nutrition and regular programs for exercise, do not lead to the resolution of OA.  Further treatment involves intra-articular injections of corticosteroids, hyaluronic acid or biologics. However, more than half of all individuals with diagnosed symptomatic knee OA have had enough progression of the disease that the only option for them becomes joint replacement.

Joint replacement

More than 3 million total joint replacement surgeries are conducted annually around the globe. From 1999 to 2008, the utilization rate of total knee replacement procedures in the U.S. more than doubled for the overall population and tripled for individuals age 45 to 64.

Coupled with increasing knee OA prevalence, the rising costs of health care may inflict a tremendous economic burden on society in the future. There are currently no medical or surgical treatments that will improve this alarming trajectory. At least 10% of joint replacement procedures are revisions.  Infection is the most devastating complication after joint replacements.

Osteomyelitis

Osteomyelitis is an infection and inflammation of the bone or the bone marrow. It can occur when a bacterial or fungal infection develops within a bone or reaches the bone from another part of the body. Bone infections can be life-threatening. They commonly affect the long bones in the leg and upper arm, the spine, and the pelvis.

Chronic osteomyelitis patients usually need both antibiotics and surgery to repair any bone damage. If the infection continues regardless high dose and prolonged antibiotic treatment and / or surgery, it may be necessary to amputate all or part of the infected limb.

Our Approach

Bone Sci. Bio Ltd. Is a specialty drug – device company, developing targeted treatments for bone and joint diseases and conditions. When our proprietary peptide hydrogel scaffold is paired with approved drugs, more effective bone healing is achieved, and systemic drug toxicity reduced.

Our BS-101 and BS-201 candidate products will address major joint preservation, joint replacement and osteomyelitis indications.

©2020 by BoneSci Bio. LTD